Cargando…
Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study
BACKGROUND: Anlotinib is a multi-target tyrosine kinase inhibitor that can effectively inhibit tumor cell proliferation after receptor kinase activation caused by KIT gene mutation. METHODS: We tested the inhibitory effect of anlotinib in GIST cell lines with different gene mutations and evaluated t...
Autores principales: | Zhou, Yongjian, Zeng, Chunling, Sun, Xiaofeng, Zhang, Jun, Qu, Hongyan, Zhang, Xinhua, Zhou, Ye, Liu, Zimin, Wu, Xiaojun, Wu, Xin, Jiao, Xuelong, Shen, Lin, Zhou, Yanbing, Wang, Yuexiang, Li, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078906/ https://www.ncbi.nlm.nih.gov/pubmed/36779523 http://dx.doi.org/10.1093/oncolo/oyac271 |
Ejemplares similares
-
Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022) -
Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
por: Joseph, Cissimol P., et al.
Publicado: (2021) -
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy
por: George, Suzanne, et al.
Publicado: (2021) -
KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors
por: Palomba, Grazia, et al.
Publicado: (2020) -
A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood
por: Zhou, Ye, et al.
Publicado: (2020)